Cargando…
The non-ergot derived dopamine agonist quinagolide in prevention of early ovarian hyperstimulation syndrome in IVF patients: a randomized, double-blind, placebo-controlled trial(†)
BACKGROUND: Ovarian hyperstimulation syndrome (OHSS) seems to be induced by the ovarian release of vascular endothelial growth factor (VEGF), which increases vascular permeability. Dopamine agonists inhibit VEGF receptor phosphorylation and thereby decrease vascular permeability. METHODS: A randomiz...
Autores principales: | Busso, Cristiano, Fernández-Sánchez, Manuel, García-Velasco, Juan Antonio, Landeras, José, Ballesteros, Augustín, Muñoz, Elkin, González, Sandra, Simón, Carlos, Arce, Joan-Carles, Pellicer, Antonio |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2839910/ https://www.ncbi.nlm.nih.gov/pubmed/20139430 http://dx.doi.org/10.1093/humrep/deq005 |
Ejemplares similares
-
Comparison of Cabergoline and Quinagolide in Prevention
of Severe Ovarian Hyperstimulation Syndrome among
Patients Undergoing Intracytoplasmic Sperm Injection
por: Taheripanah, Robabeh, et al.
Publicado: (2018) -
Non-ergot dopamine agonists and heart failure
por: Şener, Yusuf Ziya, et al.
Publicado: (2019) -
Total Synthesis of (±)-Quinagolide: A Potent
D(2) Receptor Agonist for the Treatment of Hyperprolactinemia
por: Chavan, Subhash P., et al.
Publicado: (2019) -
Incidence of heart valve disease in women treated with the ergot-derived dopamine agonist bromocriptine
por: Clausen, Marianne F., et al.
Publicado: (2021) -
Quinagolide Treatment Reduces Invasive and Angiogenic Properties of Endometrial Mesenchymal Stromal Cells
por: Iampietro, Corinne, et al.
Publicado: (2022)